Minerva Neurosciences | NERV - Ingresos Por Ventas





Ventas Cambio Fecha
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Adma Biologics USD 114.5M 24.66M 2026-03
ALKERMES USD 392.91M 8.41M 2026-03
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
AstraZeneca USD 15.29B 213M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Cipla INR 65.41B 9.77B 2026-03
Clal Biotechnology ILS 3.41M 2M 2022-12
Compugen USD 6.35M 60.98M 2026-03
CSL USD 8.33B 4.79B 2025-12
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
GlaxoSmithKline GBP 7.63B 991M 2026-03
Grifols EUR 2B 306.7M 2026-03
Halozyme Therapeutics USD 377M 74.76M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
J&J USD 24.1B 500M 2026-03
Merck USD 16.29B 110M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 13.11B 226M 2026-03
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 14.5B 3.08B 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.24B 60M 2026-03
Takeda JPY 1.09T 100B 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12